Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative

• Published in: Translational and clinical pharmacology Vol. 27; no. 1; pp. 12 - 18
• Main Authors: Park, Jin-Sol, Jeon, Ji-Young, Yang, Ji-Ho, Kim, Min-Gul
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Society for Clinical Pharmacology and Therapeutics 01.03.2019; 대한임상약리학회
• Subjects: Review; 의약학; Torsade de Pointes; CiPA; Cardiotoxicity
• ISSN: 2289-0882; 2383-5427
• DOI: 10.12793/tcp.2019.27.1.12

In 2005, the International Council for Harmonization (ICH) established cardiotoxicity assessment guidelines to identify the risk of Torsade de Pointes (TdP). It is focused on the blockade of the human ether-à-go-go-related gene (hERG) channel known to cause QT/QTc prolongation and the QT/QTc prolongation shown on the electrocardiogram. However, these biomarkers are not the direct risks of TdP with low specificity as the action potential is influenced by multiple channels along with the hERG channel. Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative emerged to address limitations of the current model. The objective of CiPA is to develop a standardized model of a human ventricular cell to quantitively evaluate the cardiac response for the cardiac toxicity risk and to come up with a metric for the TdP risk assessment. working group under CiPA developed a standardized and reliable model and a metric that can quantitatively evaluate cellular cardiac electrophysiologic activity. The implementation mainly consists of hERG fitting, Hill fitting, and action potential simulation. In this review, we explained how the model of CiPA works, and briefly summarized current overall CiPA studies. We hope this review helps clinical pharmacologists to understand the underlying estimation process of CiPA modeling.